Approval Letter Other 761126 (Jan 1, 2025)

Summary

This document is a Complete Response letter from the FDA to Tanvex BioPharma USA, Inc. for their Biologics License Application (BLA) 761126 for TX01. The FDA has determined that the application cannot be approved in its present form due to unresolved deficiencies related to facility inspections, comparative analytical assessment data, and requirements for labeling, proprietary name resubmission, and safety updates.

Key points

• Satisfactorily resolve deficiencies identified during manufacturing facility inspections, with verification by the FDA.
• Provide reliable data collected using binding assays demonstrated to be fit for their intended use to support the comparative analytical assessment of G-CSF receptor binding affinity between TX01 and U.S.-licensed Neupogen.
• Ensure the comparative analytical assessment includes lots of the proposed TX01 commercial material and TX01 lots used in clinical studies (or representative material with appropriate justification).
• If labeling is revised, use the Selected Requirements for Prescribing Information (SRPI) checklist to ensure conformity with format items in regulations and guidances.
• Include updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.
• Resubmit the proposed proprietary name (Nypozi) when responding to the application deficiencies.
• Include a safety update with data from all nonclinical and clinical studies of the product, describing any significant changes or findings in the safety profile and their relevance to clinically meaningful differences between the proposed biosimilar and the U.S.-licensed reference product.
• Present new safety data from clinical studies for the proposed indication using the same format as the original BLA submission.

Cited reasons

• Manufacturing Facility Deficiencies
• Inadequate Comparative Analytical Assessment Data
• Reserved Comment on Prescribing Information and Labeling
• Proprietary Name Resubmission
• Safety Update Requirement
• The Biologics License Application for TX01 cannot be approved due to unresolved manufacturing facility deficiencies and persistent issues with the comparative analytical assessment data. Specifically, the reliability of G-CSF receptor binding assay data is questioned due to data omission and inadequate method qualification, preventing a determination of high similarity to the U.S.-licensed reference product. Additionally, comments on labeling are reserved, and a comprehensive safety update and proprietary name resubmission are required upon response.

Recommended actions

• Satisfactorily resolve deficiencies identified during manufacturing facility inspections, with verification by the FDA.
• Provide reliable data collected using binding assays demonstrated to be fit for their intended use to support the comparative analytical assessment of G-CSF receptor binding affinity between TX01 and U.S.-licensed Neupogen.
• Ensure the comparative analytical assessment includes lots of the proposed TX01 commercial material and TX01 lots used in clinical studies (or representative material with appropriate justification).
• If labeling is revised, use the Selected Requirements for Prescribing Information (SRPI) checklist to ensure conformity with format items in regulations and guidances.
• Include updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.
• Resubmit the proposed proprietary name (Nypozi) when responding to the application deficiencies.
• Include a safety update with data from all nonclinical and clinical studies of the product, describing any significant changes or findings in the safety profile and their relevance to clinically meaningful differences between the proposed biosimilar and the U.S.-licensed reference product.
• Present new safety data from clinical studies for the proposed indication using the same format as the original BLA submission.

Deficiency summary

The Biologics License Application for TX01 cannot be approved due to unresolved manufacturing facility deficiencies and persistent issues with the comparative analytical assessment data. Specifically, the reliability of G-CSF receptor binding assay data is questioned due to data omission and inadequate method qualification, preventing a determination of high similarity to the U.S.-licensed reference product. Additionally, comments on labeling are reserved, and a comprehensive safety update and proprietary name resubmission are required upon response.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

BLA 351(k)

Impact

Impact score

0.75

Estimated delay

300 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary obstacles to approval are unresolved manufacturing quality system deficiencies and a lack of robust, reliable comparative analytical data to demonstrate high similarity, particularly concerning receptor binding assays. The application requires significant data and facility remediation before it can be reconsidered.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 25%